Target- |
MechanismImmunostimulants |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH
0 Patents (Medical) associated with igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH
100 Deals associated with igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH
100 Translational Medicine associated with igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH